White paper
GLP-1 anti-obesity medications: A new frontier in the fight against obesity
-
Michelle Friedman
-
Shaila Yoshida
Explore the evolving landscape of anti-obesity medications (AOMs) in this comprehensive white paper, focused on GLP-1 receptor agonists: a powerful class of treatments revolutionizing obesity care. From the clinical efficacy of FDA-approved medications like Wegovy® and Zepbound® to payer coverage challenges, regulatory updates, and future market projections, this resource provides critical insights for healthcare decision-makers, payers, providers, and policy advocates. Learn how AOMs are addressing unmet needs in obesity treatment, the economic impacts of obesity on healthcare systems, and strategies to optimize access and outcomes.
Key highlights:
- Trends in the prevalence and treatment of obesity
- Historical milestones in AOM development
- Challenges in payer coverage, supply chain, and patient adherence
- Future outlook for innovation, regulatory policy, and market growth
Discover how GLP-1 AOMs are shaping the future of obesity management and transforming patient health outcomes. Access the white paper now to stay ahead in the dynamic AOM market.
Access the white paper
Pardot Form
Connect with our team
Our commitment to helping clients achieve market access plays a crucial role in patients’ access to affordable, diverse, and effective therapies so they can achieve their best potential health outcomes. Connect with our team of experts to discover how we can help support your goals.
